#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Von Willebrand's disease Gaucher's disease type III Anal cancer Cerebellar ataxia Acute myeloid leukaemia recurrent Toxic epidermal necrolysis Mantle cell lymphoma stage III Necrotising myositis Acute graft versus host disease in liver Obliterative bronchiolitis Central nervous system lymphoma Breast angiosarcoma metastatic Polymyositis B-cell small lymphocytic lymphoma refractory Synovial sarcoma recurrent More trials…

    Learn about Rare Diseases

    Haemophilia B with anti factor IX – Treatment Congenital nephrogenic diabetes insipidus – Basic Information Acquired haemophilia Marfan’s syndrome – Life with Disease Von Willebrand’s disease – Life with Disease CADASIL – Basic Information Ehlers-Danlos syndrome – Treatment Malignant fibrous histiocytoma – Diagnostics Myxofibrosarcoma – Basic Information Splenic marginal zone lymphoma – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    MB-001 Hydrocortisone Ph. Eur. Atezolizumab Levomepromazine Hydrochloride Dersimelagon Phosphate Retinol Palmitate Soya Oil, Purified Levodropropizine T89 Linezolid Deoxyribonucleic Acid Betula Alba Pollen Extract Paroxetine Ascorbic Acid Bp Sodium Iodide (131I) Ro7790121 Apadamtase Alfa Betamethasone Emicizumab Magnesium Citrate More therapies…

    Learn about Your Condition

    Type 1 diabetes mellitus Malignant melanoma Rheumatic disorder Stomatitis Parkinson's disease Peritonitis EGFR gene mutation Alagille syndrome Systemic mastocytosis Critical illness Anaemia of chronic disease Ovarian cancer stage III High-grade B-cell lymphoma Post-acute COVID-19 syndrome Chronic fatigue syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institutul National de Diabet, Nutritie si Boli Metabolice…

Institutul National de Diabet, Nutritie si Boli Metabolice “N.C. Paulescu”

Strada Movila Ion 5-7, Bucharest, 020475, Romania

Want to learn more about this study or check if you can participate? Contact us.

  • Zenagamtide Compared with Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

    Recruiting

    3 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    • Obesity
    • Overweight
    Investigated Drugs:
    • Semaglutide
    Bulgaria Croatia Germany Hungary Poland Portugal +1

  • Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

    Recruiting

    3 1 1
    Investigated Diseases:
    • Cardiovascular disorder
    • Type 2 diabetes mellitus
    • Hypertension
    Investigated Drugs:
    • Bi 690517
    • Empagliflozin
    Austria Belgium Bulgaria Croatia Czechia Denmark +17

  • Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

    Recruiting

    3 1
    Investigated Diseases:
    • Arteriosclerosis
    Investigated Drugs:
    • Maridebart Cafraglutide
    Austria Belgium Bulgaria Czechia Denmark Finland +12

  • Study on Baxdrostat and Dapagliflozin for Preventing Heart Failure in Patients at High Risk

    Recruiting

    3 1 1
    Investigated Drugs:
    • Baxdrostat
    • Dapagliflozin
    Bulgaria Czechia Denmark France Germany Greece +8

  • Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

    Recruiting

    4 1
    Investigated Drugs:
    • Clazakizumab
    Austria Belgium Bulgaria Croatia Czechia Denmark +16

  • A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

    Not recruiting

    3 1
    Investigated Diseases:
    • Arteriosclerosis
    Austria Belgium Czechia Denmark France Germany +8

  • Inclisiran for Preventing Cardiovascular Events in High-Risk Primary Prevention Patients with Atherosclerotic Cardiovascular Disease

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Arteriosclerosis
    Investigated Drugs:
    • Inclisiran
    Austria Belgium Bulgaria Croatia Czechia Denmark +14

  • Study comparing cagrilintide and semaglutide versus tirzepatide in people with type 2 diabetes taking metformin or SGLT2 inhibitor

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Cagrilintide
    • Semaglutide
    • Tirzepatide
    Germany Greece Hungary Poland Romania Spain

  • A study comparing cagrilintide and semaglutide combination to semaglutide, cagrilintide, and placebo in adults with type 2 diabetes on metformin

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Metformin
    • Cagrilintide
    • Dapagliflozin
    Bulgaria Croatia Czechia Denmark Finland Germany +9

  • Study of oral and injectable NNC0487-0111 (Amycretin) to find the best dose for blood sugar control in adults with type 2 diabetes taking metformin with or without SGLT2 inhibitor

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Dapagliflozin Propanediol
    • Metformin Embonate
    Bulgaria Croatia Germany Greece Hungary Poland +3
1 2
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!